when a high dose of drug is administered to tumor bearers with a fully developed antitumor immune response , it is more likely to lead to potentiation of host antitumor immunity than when the high dose of drug is administered to tumor bearers that have not yet achieved the full maturity of their antitumor immune response .
C0020964
immunity
C1516031
antitumor